Prof. Jiajun Liu: Interpretation of the research progress of geratinib in the treatment of FLT3-mutated R/R AML patients
Time of Update: 2022-11-05
Gilteritinib is an oral, highly specific second-generation type I FMS-like tyrosine kinase 3 (FLT3) inhibitor capable of simultaneously inhibiting FLT3-ITD and FLT3-TKD mutations, and the phase III AD
What are the long-term benefits of Allo-HSCT in elderly patients with CR1 AML
Time of Update: 2022-04-27
Table 2 Figure 1 Multivariate time-dependent Cox model showing that allo-HSCT was associated with a significantly lower risk of recurrence (73% risk reduction; HR [95% CI], 0.
allo-HSCT improves outcomes in ELN IR and UR AML patients aged >60 years in CR1 .
New drug for leukemia! Astellas second-generation FLT3 inhibitor Xospata has been approved by the FDA to treat relapse/difficulty
Time of Update: 2021-02-17
FDA approval of Xospata is based on an interim analysis of the following endpoints in ADMIRAL clinical studies: Full Remission Rate (CR)/Complete Remission (CRh), CR/CRh Remission Duration (DOR), conversion rate dependent on blood transfusion to non-dependent blood transfusion.
Blood:Phase 3 trial: Two sets of BTK inhibitors to treat Fahrenheit globulinemia
Time of Update: 2020-08-22
29 (28%) and 19 (19%) patients in the zanubrutinib and Irutinib groups received VGPR, respectively, but the differences between the two groups were not statistically significant (P-0.09); did not reach the mid-level DOR and PFS, and the 18-month non-progress survival rates of the Irutini and Zanubrutinib groups were 84% and 85%, respectively.
The first new drug in 20 years! AstraZeneca immunotoxin lumoxiti applied for listing in the European Union to treat hair cell leukemia (HCl
Time of Update: 2020-01-04
January 4, 2020 / BIOON / -- the French pharmaceutical company, innate Pharma SA, recently announced that the European Drug Administration (EMA) has accepted lumoxiti (moxetummab Pasudotox's marketing
1.3 billion "Thunderbolt" of pharmaceutical enterprises! Seven companies lost two or more than 1 billion yuan this year
Time of Update: 2019-12-16
Recently, Haizheng pharmaceutical announced that it would withdraw 1.317 billion yuan for impairment of various assets and reduce the company's net profit this year accordingly Data shows that Haizhen